Research progress of the relationship between endothelin and hypertensive renal damage

doi:10.3877/cma.j.issn.2095-3216.2019.06.009

Abstract

Abstract:

Hypertensive renal damage refers to renal structural and functional damage caused by essential hypertension. Hypertension and renal damage are causal to each other and promote the development of pathological changes. Endothelin (ET) system can regulate blood pressure and renal blood flow through various mechanisms, which is closely related to the occurrence and development of hypertensive renal damage. Endothelin receptors antagonists (ERAs) can block the effect of endothelin by acting on endothelin receptors (ETRs), thereby lowering blood pressure, improving renal function, and delaying the progression of hypertensive renal damage.

Key words: Endothelin, Endothelin receptors antagonists, Hypertensive renal damage

Ting Zhang, Xun Liu, Xiaofei Wang, Xiaoying Lu, Hongbin Zou. Research progress of the relationship between endothelin and hypertensive renal damage[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2019, 08(06): 273-276.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2019.06.009

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2019/V08/I06/273

References 39

[1]	Yanagisawa M, Massaki T. Molecular biology and biochemistry of the endothelins [J]. Trends Pharmacol Sci, 1989, 10(9): 374-378.
[2]	张珂，陈鹊汀，王晓冬，等．内皮素受体的分布及其生物功能[J]．医学研究与教育，2014，31(3):76-81.
[3]	Houde M, Desbiens L, D′Orléans－Juste P. Endothelin－1: biosynthesis, signaling and vasoreactivity [J]. Adv Pharmacol, 2016, 77: 143-175.
[4]	邵子月，史虓悦，陈磊，等．内皮素与高血压相关性的研究进展[J]．中国现代医药杂志，2017，19(8):92-94.
[5]	梁荣章，吴永泉，邓朝胜．内皮素通路在靶向治疗慢性血栓栓塞性肺动脉高压中的作用及机制[J]．中华高血压杂志，2018，26(10):919-922.
[6]	Gohar EY, Giachini FR, Pollock DM, et al. Role of the endothelin system in sexual dimorphism in cardiovascular and renal diseases [J]. Life Sci, 2016, 15(159): 20-29.
[7]	Drexler H, Hornig B. Endothelial dysfunction in human disease [J]. J Mol Cell Cardiol, 1999, 31(1): 51-60.
[8]	史小映，张玉顺，龙昌柏．CTGF与低氧性肺血管重构的关系及波生坦的调控作用[J]. 临床医学研究与实践，2018，3(33):12-14, 25.
[9]	Trindade M, Oigman W, Fritsch Neves M. Potential role of endothelin in early vascular aging [J]. Curr Hypertens Rev, 2017, 13(1): 33-40.
[10]	王琪，程兆忠，王镜銮，等．内皮素－1在肺动脉高压发病中作用的研究进展[J]．心血管病防治知识(学术版)，2018，(4):93-96.
[11]	Boesen EI. Endothelin receptors, renal effects and blood pressure [J]. Curr Opin Pharmacol, 2015, 21: 25-34.
[12]	张洁，高秀林．内皮素及其受体拮抗剂对慢性肾脏病的影响[J]．中华保健医学杂志，2010，12(2):147-149.
[13]	范景如，郭舜奇．内皮素受体拮抗剂在高血压治疗中的研究进展[J]．中华高血压杂志，2017，25(7):632-635.
[14]	赵狄，叶鹏，Dhaun N，et al.慢性肾脏病患者血压与动脉僵硬度的昼夜变化：内皮素1的作用[J]．中华高血压杂志，2014，22(7):685.
[15]	Larivière R, Gauthier－Bastien A, Ung RV, et al. Endothelin type A receptor blockade reduces vascular calcification and inflammation in rats with chronic kidney disease [J]. J Hypertens, 2017, 35(2): 376-384.
[16]	王勇，吴俊姝，常淑萍．慢性肾脏病患者血清内皮素和一氧化氮水平变化的研究[J]．山西医药杂志(下半月刊)，2012，41(8):810-811.
[17]	Garsen M, Lenoir O, Rops AL, et al. Endothelin－1 induces proteinuria by heparanase－mediated disruption of the glomerular glycocalyx [J]. J Am Soc Nephrol, 2016, 27(12): 3545-3551.
[18]	Neuhofer W, Pittrow D. Endothelin receptor selectivity in chronic kidney disease: rationale and review of recent evidence [J]. Eur J Clin Invest, 2009, 39(Suppl 2): 50-67.
[19]	Seccia TM, Caroccia B, Gioco F, et al. Endothelin-1 drives epithelial－mesenchymal transition in hypertensive nephroangiosclerosis [J]. J Am Heart Assoc, 2016, 5(7): e003888.
[20]	Coelho SC, Berillo O, Caillon A, et al. Three－month endothelial human endothelin－1 overexpression causes blood pressure elevation and vascular and kidney injury [J]. Hypertension, 2017, 71(1): 208-216.
[21]	Tobe S, Kohan DE, Singarayer R. Endothelin receptor antagonists: new hope for renal protection? [J]. Curr Hypertens Rep, 2015, 17(7): 57.
[22]	Davenport AP, Hyndman KA, Dhaun N. et al. Endothelin [J]. Pharmacol Rev, 2016, 68(2): 357-418.
[23]	Correale M, Ferraretti A, Monaco I, et al. Endothelin－receptor antagonists in the management of pulmonary arterial hypertension: where do we stand? [J]. Vasc Health Risk Manag, 2018, 14: 253-264.
[24]	Yuan W, Cheng G, Li B, et al. Endothelin－receptor antagonist can reduce blood pressure in patients with hypertension: a meta－analysis [J]. Blood Press, 2017, 26(3): 139-149.
[25]	宋洁，余再新．内皮素受体拮抗剂在肺动脉高压治疗中的应用[J]．临床药物治疗杂志，2013，11(6):5-10.
[26]	Raina A, Horn ET, Benza RL. The pathophysiology of endothelin in complications after solid organ transplantation: a potential novel therapeutic role for endothelin receptor antagonists [J]. Transplantation, 2012, 94(9): 885-893.
[27]	Belge C, Delcroix M. Treatment of pulmonary arterial hypertension with the dual endothelin receptor antagonist macitentan: clinical evidence and experience [J]. Ther Adv Respir Dis, 2019, 13: 1753466618823440.
[28]	顾智淳，沈节艳，刘晓琰，等．新型内皮素受体拮抗剂马西替坦：治疗肺动脉高压的一线药物[J]．中国新药与临床杂志，2015，34(2):102-106.
[29]	Steven S, Oelze M, Hausding M, et al. The Endothelin receptor antagonist macitentan improves isosorbide－5－mononitrate (ISMN) and isosorbide dinitrate (ISDN) induced endothelial dysfunction, oxidative stress, and vascular inflammation [J]. Oxid Med Cell Longev, 2018, 2018: 7845629.
[30]	Kohan DE, Pritchett Y, Molitch M, et al. Addition of atrasentan to renin－angiotensin system blockade reduces albuminuria in diabetic nephropathy [J]. J Am Soc Nephrol, 2011, 22(4): 763-772.
[31]	Boels MG, Avramut MC, Koudijs A, et al. Atrasentan reduces albuminuria by restoring the glomerular endothelial glycocalyx barrier in diabetic nephropathy [J]. Diabetes, 2016, 65(8): 2429-2439.
[32]	Koomen JV, Stevens J, Mostafa NM, et al. Defining the optimal dose of atrasentan by evaluating the exposure－response relationships of albuminuria and bodyweight [J]. Diabetes Obes Metab, 2018, 20(8): 2019-2022.
[33]	Mann JF, Green D, Jamerson K, et al. Avosentan for Overt Diabetic Nephropathy [J]. J Am Soc Nephrol, 2010, 21(3): 527-535.
[34]	Weber MA, Black H, Bakris G, et al. A selective endothelin－receptor antagonist to reduce blood pressure in patients with treatment－resistant hypertension：a randomised，double－blind，placebo－controlled trial [J]. Lancet, 2009, 374(9699): 1423-1431.
[35]	Wei A, Gu Z, Li J, et al. Clinical adverse effects of endothelin receptor antagonists: insights from the meta－analysis of 4894 patients from 24 randomized double－blind placebo－controlled clinical trials [J]. J Am Heart Assoc, 2016, 5(11): e003896.
[36]	Vaněcková I, Hojná S, Kadlecová M, et al. Renoprotective effects of ET(A) receptor antagonists therapy in experimental non－diabetic chronic kidney disease: Is there still hope for the future? [J]. Physiol Res, 2018, 67(Suppl 1): S55-S67.
[37]	Gabbay E, Fraser J, Mcneil K. Review of bosentan in the management of pulmonary arterial hypertension [J]. Vasc Health Risk Manag, 2007, 3(6): 887-900.
[38]	US Food and Drug Administration. FDA drug safety communication: liver injury warning to be removed from Letairis (ambrisentan) tablets [EB/OL]. 2011: URL
[39]	Mucke HA. Small－molecule endothelin receptor antagonists: a review of patenting activity across therapeutic areas [J]. IDrugs, 2009, 12(6): 366-375.

Please choose a citation manager

Content to export